Aussie Kaletra approval
January 27, 2011
THE Therapeutic Goods
Administration has approved
Kaletra (lopinavir/ritonavir), a oncedaily
dosing for HIV treatmentexperienced
adult patients with
HIV-1 infection, in combination
with other antiretroviral agents.
The approval follows trials which
found that daily dosings of Kaletra,
a HIV protease inhibitor, had
similar efficacy, safety and
tolerability as twice-daily dosing in
HIV patients failing their previous
antiretroviral regimen.
In addition, the once daily dosing
regime also resulted in increased
treatment adherence and limited
resistance evolution, compared to
twice-daily dosing.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jan 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jan 11